Cancer combo trial halted early: what we learned
NCT ID NCT04612712
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, donafenib and KN046, in people with advanced gastrointestinal cancers that had not responded to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The trial was stopped early, and only 15 people took part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital Affiliated to Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk